• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

增强对奥密克戎亚谱系的中和作用：二价和单价 COVID-19 加强疫苗以及最近 SARS-CoV-2 奥密克戎变异株感染的相关见解。

Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.

机构信息

College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.

Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.

出版信息

Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000.

DOI:10.1111/irv.70000
PMID:39377176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11459205/
Abstract

BACKGROUND

Omicron variants have rapidly diversified into sublineages with mutations that enhance immune evasion, posing challenges for vaccination and antibody responses. This study aimed to compare serum cross-neutralizing antibody responses against various SARS-CoV-2 Omicron sublineages (BA.1, BA.5, XBB.1.17.1, FK.1.1, and JN.1) in recipients of monovalent COVID-19 boosters, bivalent booster recipients, and individuals who had recovered from Omicron BA.5 infections.

METHODS

We conducted a micro-neutralization assay on serum samples from monovalent BNT162b2 booster recipients (N = 54), bivalent BNT162b2 booster recipients (N = 24), and SARS-CoV-2 Omicron BA.5-recovered individuals (N = 13). The history of SARS-CoV-2 Omicron infection was assessed using ELISA against the SARS-CoV-2 NP protein.

RESULTS

Bivalent booster recipients exhibited significantly enhanced neutralization efficacy against Omicron sublineages compared to those who had received monovalent booster vaccinations. Omicron BA.5-recovered individuals displayed similar neutralizing antibodies (NAbs) to the bivalent booster recipients. Despite the improved neutralization in bivalent recipients and BA.5-recovered individuals, there were limitations in neutralization against the recently emerged Omicron subvariants: XBB.1.17.1 FK.1.1, and JN.1. In both monovalent and bivalent booster recipients, a history of Omicron breakthrough infection was associated with relatively higher geometric mean titers of NAbs against Omicron BA.1, BA.5, and XBB.1.17.1 variants.

CONCLUSION

This study underscores the intricate interplay between vaccination strategies, immune imprinting, and the dynamic landscape of SARS-CoV-2 variants. Although bivalent boosters enhance neutralization, addressing the challenge of emerging sublineages like XBB.1.17.1, FK.1.1, and JN.1 may necessitate the development of tailored vaccines, underscoring the need for ongoing adaptation to effectively combat this highly mutable virus.

摘要

背景

Omicron 变体迅速分化为具有增强免疫逃逸能力的亚谱系，这给疫苗接种和抗体反应带来了挑战。本研究旨在比较单价 COVID-19 加强针、双价加强针接种者和从 Omicron BA.5 感染中康复的个体血清对各种 SARS-CoV-2 Omicron 亚谱系（BA.1、BA.5、XBB.1.17.1、FK.1.1 和 JN.1）的交叉中和抗体反应。

方法

我们对 54 名接受单价 BNT162b2 加强针、24 名接受双价 BNT162b2 加强针和 13 名从 SARS-CoV-2 Omicron BA.5 感染中康复的个体的血清样本进行了微量中和测定。使用 ELISA 检测针对 SARS-CoV-2 NP 蛋白的 SARS-CoV-2 Omicron 感染史。

结果

与接受单价加强针接种者相比，双价加强针接种者对 Omicron 亚谱系的中和效力显著增强。Omicron BA.5 康复个体显示出与双价加强针接种者相似的中和抗体（NAb）。尽管双价接受者和 BA.5 康复个体的中和作用得到改善，但对最近出现的 Omicron 亚变体 XBB.1.17.1、FK.1.1 和 JN.1 的中和作用仍存在局限性。在单价和双价加强针接种者中，Omicron 突破感染史与针对 Omicron BA.1、BA.5 和 XBB.1.17.1 变体的 NAb 几何平均滴度较高相关。

结论

本研究强调了疫苗接种策略、免疫印迹和 SARS-CoV-2 变体动态景观之间的复杂相互作用。尽管双价加强针增强了中和作用，但应对像 XBB.1.17.1、FK.1.1 和 JN.1 等新兴亚谱系的挑战可能需要定制疫苗，这突显了不断适应以有效对抗这种高度变异病毒的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/7e10c553231b/IRV-18-e70000-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/24e6581dba7a/IRV-18-e70000-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/dac320207a0c/IRV-18-e70000-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/a2af8c8412b3/IRV-18-e70000-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/7e10c553231b/IRV-18-e70000-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/24e6581dba7a/IRV-18-e70000-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/dac320207a0c/IRV-18-e70000-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/a2af8c8412b3/IRV-18-e70000-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9923/11459205/7e10c553231b/IRV-18-e70000-g004.jpg

相似文献

1
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.增强对奥密克戎亚谱系的中和作用：二价和单价 COVID-19 加强疫苗以及最近 SARS-CoV-2 奥密克戎变异株感染的相关见解。
Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000.
2
Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.对 BNT162b2 二价加强针接种后六个月时针对 XBB.1.5、BA.2.86、FL.1.5.1 和 JN.1 的中和抗体反应。
Int J Infect Dis. 2024 Jun;143:107028. doi: 10.1016/j.ijid.2024.107028. Epub 2024 Apr 5.
3
Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.奥密克戎 XBB.1.5 和 JN.1 变异株经 COVID-19 加强针接种和感染后的中和作用。
J Med Virol. 2024 Jul;96(7):e29801. doi: 10.1002/jmv.29801.
4
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.第四剂二价 COVID-19 疫苗在诱导对奥密克戎亚变种的交叉反应性记忆 B 细胞方面优于单价加强针。
J Infect. 2024 Oct;89(4):106246. doi: 10.1016/j.jinf.2024.106246. Epub 2024 Aug 8.
5
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.比较携带早期和晚期 SARS-CoV-2 变异株刺突的单价和双价腺病毒疫苗的免疫原性。
Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.
6
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.重组XBB.1.5加强针可诱导对包括KP.2和KP.3在内的JN.1亚谱系产生强大的中和作用。
Signal Transduct Target Ther. 2025 Jan 27;10(1):47. doi: 10.1038/s41392-025-02139-5.
7
A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults.一项关于原型疫苗、单价适配疫苗和二价疫苗针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）野生型、奥密克戎BA.1和奥密克戎BA.4/5在健康成年人中的免疫原性的荟萃分析。
Virology. 2025 May;606:110509. doi: 10.1016/j.virol.2025.110509. Epub 2025 Mar 19.
8
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients.肝移植受者接种XBB.1.5加强针后对SARS-CoV-2 XBB.1.5和JN.1变体的免疫反应
Viruses. 2024 Dec 19;16(12):1942. doi: 10.3390/v16121942.
9
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.XBB.1.5单价疫苗可诱导对SARS-CoV-2变体（如HV.1和JN.1）以及SARS-CoV-1产生持久的交叉反应，但产生的XBB.1.5特异性抗体有限。
mBio. 2025 Apr 9;16(4):e0360724. doi: 10.1128/mbio.03607-24. Epub 2025 Mar 5.
10
Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.在 5-11 岁儿童中使用二价 DS-5670a/b 进行加强免疫接种是安全的，并且针对 SARS-CoV-2 变异株具有免疫原性：一项 2/3 期、随机、主动对照研究。
Front Immunol. 2024 Sep 2;15:1445459. doi: 10.3389/fimmu.2024.1445459. eCollection 2024.

本文引用的文献

1
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.奥密克戎 XBB 和 BA.2.86/JN.1 分支的 SARS-CoV-2 具有不同的进化特征，表现为适应性增强和抗体逃避能力提高。
Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7.
2
Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.二价 mRNA 疫苗在 SARS-CoV-2 初免和既往感染人群中预防有医疗干预的症状性 SARS-CoV-2 感染和 COVID-19 相关住院的有效性：一项回顾性队列研究。
Lancet Infect Dis. 2023 Dec;23(12):1343-1348. doi: 10.1016/S1473-3099(23)00373-0. Epub 2023 Aug 2.
3
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.重复接种疫苗诱导产生的IgG4抗体可能会对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白产生免疫耐受。
Vaccines (Basel). 2023 May 17;11(5):991. doi: 10.3390/vaccines11050991.
4
Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review.临床病毒学以及 COVID-19 疫苗和单克隆抗体对高传染性 SARS-CoV-2 奥密克戎变异株 BF.7（BA.5.2.1.7）的影响：系统评价。
Virology. 2023 Jul;584:38-43. doi: 10.1016/j.virol.2023.04.007. Epub 2023 May 19.
5
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.SARS-CoV-2 S2 亚基中可靶向的元件用于设计泛冠状病毒融合抑制剂和疫苗。
Signal Transduct Target Ther. 2023 May 10;8(1):197. doi: 10.1038/s41392-023-01472-x.
6
Statement on the update of WHO's working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest.世界卫生组织关于关注的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株和感兴趣的变异株工作定义及追踪系统更新的声明。
Saudi Med J. 2023 Apr;44(4):427.
7
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.令人担忧的 SARS-CoV-2 BQ 和 XBB 亚型不断出现的抗体逃逸特性。
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
8
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.来自mRNA二价加强针的针对BA.2.75.2、BQ.1.1和XBB的中和作用。
N Engl J Med. 2023 Jan 12;388(2):183-185. doi: 10.1056/NEJMc2214293. Epub 2022 Dec 21.
9
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB.奥密克戎亚变体BQ.1.1和XBB的体液免疫逃逸
Lancet Infect Dis. 2023 Jan;23(1):30-32. doi: 10.1016/S1473-3099(22)00816-7. Epub 2022 Dec 7.
10
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.